Last updated: February 20, 2024
Sponsor: Jasper Gerritsen
Overall Status: Active - Recruiting
Phase
N/A
Condition
Brain Cancer
Gliomas
Brain Tumor
Treatment
Supramaximal resection
Maximal safe resection
Clinical Study ID
NCT06118723
MEC-2020-0812-2
Ages 18-90 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age ≥18 years and ≤90 years
- Tumor diagnosed as HGG (WHO grade III/IV) on MRI as assessed by the neurosurgeon
- Written informed consent
Exclusion
Exclusion Criteria:
- Tumors of the cerebellum, brainstem or midline
- Multifocal contrast enhancing lesions
- Medical reasons precluding MRI (e.g. pacemaker)
- Inability to give written informed consent
- Secondary high-grade glioma due to malignant transformation from low-grade glioma
- Second primary malignancy within the past 5 years with the exception of adequatelytreated in situ carcinoma of any organ or basal cell carcinoma of the skin
Study Design
Total Participants: 784
Treatment Group(s): 2
Primary Treatment: Supramaximal resection
Phase:
Study Start date:
January 01, 2022
Estimated Completion Date:
January 01, 2028
Study Description
Connect with a study center
University Hospitals Leuven
Leuven, 3000
BelgiumActive - Recruiting
Universitätsklinikum Heidelberg
Heidelberg, Baden-Württemberg 69120
GermanyActive - Recruiting
Technical University Munich
Munich, Bavaria 74076
GermanySite Not Available
Erasmus Medical Center
Rotterdam, Zuid-Holland 3015 GD
NetherlandsActive - Recruiting
Haaglanden Medical Centre
The Hague, Zuid-Holland 2512 VA
NetherlandsActive - Recruiting
Inselspital Universitätsspital Bern
Bern, 3010
SwitzerlandSite Not Available
University of California, San Francisco (UCSF)
San Francisco, California 94143
United StatesActive - Recruiting
Massachusetts General Hospital
Boston, Massachusetts 02114
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.